ࡱ> @B?C bjbjnn =( h h % """""6668n$,6;;;#%%%%%%$r("I";";;;I""E^;F""#;#:c,ȒV t0 ###"l;;;;;;;II;;;;;;;#;;;;;;;;; X : BPNSU LETTER OF UNDERSTANDING The BPNSU Committee has approved the_________________________ study and we are looking forward to placing it on the BPNSU website. There are some particular points that need to be agreed between the investigator and the BPNSU. I Contributions The contributions are 1200 for up to 2 years (even if a project is 1 year) of your study. The total BPNSU fee is payable in advance of the study start date. The BPNA Secretariat will send an invoice to you as soon as your project is added to the BPNSU website. Any extra years that may be added would be a further 600 per year.. The contribution rate is reviewed annually. If a study is extended beyond its original agreed period, the contribution for the extra period will be at the rate applicable in the first month of the extension. The BPNSU reserves the right to vary the contribution requested in individual cases should special circumstances apply, and to make additional charges for any extra expenses beyond those usually involved. II Conduct of the Study a) Investigators will provide the BPNSU office with any revised documents relating to the study, preferably on CD. b) You are asked to produce short summaries about study progress for the BPNSU on an annual basis. Annual reports will be submitted by November 1st each year. This gives us an opportunity to publicise the study and report on its progress at the annual BPNA scientific meeting. c) You should be willing to answer queries from involved clinicians. It is important that any cases that may come direct to you and NOT through the BPNSU are eventually notified to the BPNSU to allow its performance to be assessed. Ethical approval for this study is the responsibility of the investigator. If you have not yet done so please supply documentation that confirms ethical approval for this study from your REC or a letter from your REC indicating that ethical approval is not necessary. III Reporting Study Findings The study has been approved by the BPNSU because important clinical or public health issues are being addressed so publication of the findings is expected. Material for publication should be prepared within a year of final data collection, and the Scientific Coordinator should be sent a draft copy of the study report before it goes for publication. The BPNSU can advise on the wording of any BPNSU methodology section used in the paper. Content and title of papers and presentations are entirely at the discretion of the researcher. The BPNSU does not require its acknowledgement in the title of a paper or collectively in the list of authors. However, when a member of the committee contributes to a project to such an extent that the study or resulting paper could not be completed without the contribution, consideration should be given to the inclusion of that individual as an author on any publication, in accordance with existing recommendations regarding authorship of scientific papers. c) The BPNSU and the clinicians should be acknowledged in any relevant papers or presentations. Finally please let me know of any problems that arise during the survey and of any other advice or assistance you may require. Yours sincerely Dr Sukhvir Wright On behalf of the BPNSU Core Group  HYPERLINK "mailto:s.wright5@aston.ac.uk" s.wright5@aston.ac.uk  BPNSU LETTER OF UNDERSTANDING I/we have read and agreed to the conditions outlined in the BPNSU letter of understanding. Signed Date .     Version 2. March 2023        - p r s   a c d e f 6 7 S      ! " # ' S ѵ}o}}}ooѩhCJOJQJ^JaJh~=CJOJQJ^JaJh@CJOJQJ^JaJh3NCJOJQJ^JaJh3NCJOJQJ^Jh3NOJQJ^JaJh3N@CJOJQJ^JaJh3N@CJOJQJ^Jh3N5@CJOJQJ^J!h3N5@CJOJQJ^JaJ+      e f 6 7     & F 9r ^gd3N$ 0*$a$gd3N$ & F 0*$^a$gd3N^gd3N & F ^gdgd3N$a$gd3N $ 0*$a$gd3N $ 0*$a$gd3N   ! " # $ & F 0*$^a$gd3N$ 0%*$^`%a$gd3N$ 0*$^a$gd3N $^`$gd3N^gd3N$a$gd3Ngd3N  9r gd3N * , S SSSSSZ[SS÷!h3N5@CJOJQJ^JaJh3NOJQJ^Jh3NOJQJ^JaJh3N@CJOJQJ^Jh3NCJOJQJ^JaJ!h3N@CJH*OJQJ^JaJh3N@CJOJQJ^JaJ8Z[^gd3N & Fgd3Ndhgd3N$ & F 0*$a$gd3Ngd3N$a$gd3N$ 0*$^a$gd3N $ 0*$a$gd3N[)*,KL $  *$a$gd3N $ 0*$a$gd3N$ 0*$^a$gd3N nW^n`Wgd3Ndhgd3Nn^ngd3N'()*+,9KLqbbbbbbbbbbXh3NOJQJ^Jh3N5@CJOJQJ^J1jh5@CJOJQJU^JmHnHu"h`0J@CJOJQJ^JaJh`@CJOJQJ^JaJ'jh`@CJOJQJU^JaJh3N@CJOJQJ^JaJ!h3N5@CJOJQJ^JaJ!h`5@CJOJQJ^JaJh`CJOJQJ^JaJdhgd3NhE|hYrh~=hVh<4jh<4UhFyOJQJ^J; 0PP&P 1A. A!r"r#$%R x2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@66666_HmH nH sH tH @`@ 3NNormalCJ_HaJmH sH tH ^@^ 3N Heading 2$$ *$@&a$5@OJQJaJtH DA D Default Paragraph FontViV  Table Normal :V 44 la (k (No List LB@L 3N Body Text$ 0*$a$ CJaJtH fR@f 3NBody Text Indent 2$ 0v*$^va$ CJaJtH NS@N 3NBody Text Indent 3$h^ha$4@"4 3NHeader  9r 4 @24 VFooter  9r 6U`A6 ` Hyperlink >*B*phcRv!QR `0Unresolved MentionB*ph`^\q PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vj\{cp/IDg6wZ0s=Dĵw %;r,qlEآyDQ"Q,=c8B,!gxMD&铁M./SAe^QשF½|SˌDإbj|E7C<bʼNpr8fnߧFrI.{1fVԅ$21(t}kJV1/ ÚQL×07#]fVIhcMZ6/Hߏ bW`Gv Ts'BCt!LQ#JxݴyJ] C:= ċ(tRQ;^e1/-/A_Y)^6(p[_&N}njzb\->;nVb*.7p]M|MMM# ud9c47=iV7̪~㦓ødfÕ 5j z'^9J{rJЃ3Ax| FU9…i3Q/B)LʾRPx)04N O'> agYeHj*kblC=hPW!alfpX OAXl:XVZbr Zy4Sw3?WӊhPxzSq]y '( $$$'   [   ' X8@(  bB  S Dh#" ?B S  ?* f%ft \b % 33333))-prsd ) ))-prsd ) z %Xu5_kȰX0^`0o()))^)`o()5_kz L=Fy~_)<4I3NWxjW]]E|VhR~=H`yYr @ p@UnknownG.[x Times New Roman5Symbol3. .[x Arial7..{$ CalibriY CG TimesTimes New RomanC.,.{$ Calibri LightA$BCambria Math"h;GsG  !rA20 3Q@P ?3N2!xxxN BPNSU LETTER OF UNDERSTANDINGAidan9Katerina Roumelioti (Membership & Committees Coordinator)  Oh+'0 4@ ` l x BPNSU LETTER OF UNDERSTANDINGAidanNormal<Katerina Roumelioti (Membership & Committees Coordinator)5Microsoft Office Word@Ik@2'Q@b܈V  ՜.+,D՜.+,H hp|  ICH  BPNSU LETTER OF UNDERSTANDING Title 8@ _PID_HLINKSAta mailto:s.wright5@aston.ac.uk  !"#$%&'()*+,-.012345689:;<=>ARoot Entry FȒVCData 1Table#WordDocument=(SummaryInformation(/DocumentSummaryInformation87CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q